Additional Treatment Using Transcatheter Arterial Infusion with Drug-Eluting Beads Transarterial Chemoembolization Contributes to Prolonged Survival of Patients with BCLC Stage C Hepatocellular Carcinoma after Discontinuing Lenvatinib: Preliminary Study

Review Data

Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for

researchers?

A: Good

Abstract & Keywords

Q: Are all required components included in the abstract? Are the keywords appropriately chosen?

A: Very good

Goal

Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?

A: Very good

Structure

Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?

A: Good

Tools and Methods

Q: Are methods the author uses adequate and well used?

A: Good

Discussion & Conclusion

Q: Is it related to the results presented before? Do you consider them as coherent?

A: Very good

Comments:

The Discussion is well supported with the observations and it provides useful information relevant to this study. The limitations of this study are also properly addressed in this section. The study findings are appropriately presented. Figures and tables are briefly explained.

Literature

Q: Does the author utilize relevant literature?

A: Good

Author's knowledge

Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?

A: Very good

Length

Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?

A: Good

Figures & Tables

Q: Does the author use them suitably? Are legend and notations clear?

A: Very good

Writing style

Q: Is it clear and understandable?

A: Good

Further comments on the paper

Comments: This single-center cohort study, involving 12 Barcelona Clinic Liver Cancer (BCLC) stage C Hepatocellular Carcinoma (HCC) patients, focuses on the significance of transcatheter arterial infusion (TAI) with drug-eluting beads transarterial chemoembolization (DEB-TACE) and DDP-H as a feasible second-line treatment after discontinuing lenvatinib. This is the first known study which shows that the second-line treatment after discontinuation of lenvatinib is associated with prolonged overall survival of BCLC stage C HCC patients. The improvement of immuno-nutritional status of these patients, assessed by controlling nutritional status (CONUT) score is a major outcome of this study. However, the retrospective nature and very small sample size are two main limitations of this study which needs to be resolved in future clinical trials. Few modifications are required in the manuscript due to a high plagiarism score that is 21%.

Q: Would you recommend this manuscript for further publication?

A: Corrections - Suitable for publishing after corrections

If you have any questions and clarifications you can write to the journal at [email protected]

Thanks,
Science Repository Team